Literature DB >> 30391833

PTSD psychotherapy improves blood pressure but leaves HPA axis feedback sensitivity stable and unaffected: First evidence from a pre-post treatment study.

Christine F Schubert1, Monika Schreckenbach2, Thomas Kirmeier3, Dominique J Gall-Kleebach4, Bastian Wollweber2, Dominik R Buell2, Manfred Uhr5, Rita Rosner6, Ulrike Schmidt7.   

Abstract

Although key to development of tailored drugs for augmentation treatment of psychotherapy for posttraumatic stress disorder (PTSD), the biological correlates of PTSD remission are still unknown, probably because pre-post treatment studies searching for them are rare. Not even the feedback sensitivity of the otherwise well-studied hypothalamic-pituitary-adrenal (HPA) axis nor arterial blood pressure (BP), which was previously reported to be elevated in PTSD patients, have so far been analyzed during PTSD treatment. To narrow this knowledge gap, we first performed an overnight dexamethasone suppression test (DST) in a mixed-sex cohort of 25 patients with severe PTSD vs. 20 non-traumatized healthy controls (nt-HC). In addition to hormones, BP and heart rate (HR) were measured at each of the four assessment points (APs). Second, the same parameters were assessed again in 16 of these patients after 12 sessions of integrative trauma-focused cognitive behavioral therapy (iTF-CBT). In relation to nt-HC, PTSD patients showed a significant elevation in HR and diastolic BP while their systolic BP, DST outcomes and basal serum cortisol levels (BSCL) were not significantly altered. In response to iTF-CBT, PTSD symptoms and dysfunctional stress coping strategies improved significantly in PTSD patients. Most important, also their systolic and diastolic BP levels ameliorated at distinct APs while their DST outcomes and BSCL remained unchanged. To our knowledge, this is the first pre-post treatment study assessing the stability of the DST outcome and BP levels during PTSD treatment. Our results provide first evidence for a non-involvement of HPA axis feedback sensitivity in PTSD symptom improvement and, furthermore, suggest a possible role for BP-regulating pathways such as the sympathetic nervous system in PTSD remission. Limitations arise from the small sample size, the lack of an untreated patient group and drug treatment of patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30391833     DOI: 10.1016/j.psyneuen.2018.10.013

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  5 in total

1.  Sexual Desire among Veterans Receiving Prolonged Exposure Therapy for PTSD: Does Successful PTSD Treatment Also Yield Improvements in Sexual Desire?

Authors:  Christal L Badour; Keith S Cox; Jessica R M Goodnight; Jessica Flores; Peter W Tuerk; Sheila A M Rauch
Journal:  Psychiatry       Date:  2019-10-02       Impact factor: 2.458

2.  Clinically meaningful posttraumatic stress disorder (PTSD) improvement and incident hypertension, hyperlipidemia, and weight loss.

Authors:  Jeffrey F Scherrer; Joanne Salas; Matthew J Friedman; Beth E Cohen; F David Schneider; Patrick J Lustman; Carissa van den Berk-Clark; Kathleen M Chard; Peter Tuerk; Sonya B Norman; Paula P Schnurr
Journal:  Health Psychol       Date:  2020-03-30       Impact factor: 4.267

3.  PTSD symptom decrease and use of weight loss programs.

Authors:  Jeffrey F Scherrer; Joanne Salas; Kathleen M Chard; Peter Tuerk; Carissa van den Berk-Clark; F David Schneider; Beth E Cohen; Patrick J Lustman; Paula P Schnurr; Matthew J Friedman; Sonya B Norman
Journal:  J Psychosom Res       Date:  2019-10-15       Impact factor: 3.006

4.  Posttraumatic Stress Disorder Treatment Effects on Cardiovascular Physiology: A Systematic Review and Agenda for Future Research.

Authors:  Kyle J Bourassa; Rebecca C Hendrickson; Greg M Reger; Aaron M Norr
Journal:  J Trauma Stress       Date:  2020-12-05

Review 5.  How does PTSD treatment affect cardiovascular, diabetes and metabolic disease risk factors and outcomes? A systematic review.

Authors:  Carissa van den Berk Clark; Vruta Kansara; Margarita Fedorova; Tiffany Ju; Tess Renirie; Jaewon Lee; Jesse Kao; Emmanuel T Opada; Jeffrey F Scherrer
Journal:  J Psychosom Res       Date:  2022-03-23       Impact factor: 4.620

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.